# Biodexa (BDRX) — News

BDRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bdrx/news

## Recent headlines

- [PLC Resources Ltd - Geo-spectral survey commences at Abbotts Gold project, WA](https://www.ainvest.com/news/plc-resources-geo-spectral-survey-commences-abbotts-gold-project-wa-2610) — AInvest Wire, Oct 13, 2026
  PLC Resources Ltd (ASX: PLC) has announced the commencement of a geo-spectral survey at its Abbotts Gold project in Western Australia. The survey is part of the company’s ongoing exploration efforts to identify potential gold-bearing structures within the project area. Geo-spectral surveys utilise…
- [Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational phase 3 trial in FAP](https://www.ainvest.com/news/biodexa-announces-serenta-milestone-100-patients-enrolled-registrational-phase-3-trial-fap-2610) — AInvest Wire, Oct 13, 2026
  Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has reached a significant milestone in its clinical development program, with the enrollment of 100 patients in its registrational Phase 3 trial for eRapa in the treatment of Familial Adenomatous Polyposis (FAP). This achievement marks a key step forward…
- [Biodexa Pharmaceuticals - ADS ratio change to 1 ADS per 400 ordinary shares from 1 per 50, effective about October 26, 2026 - SEC filing](https://www.ainvest.com/news/biodexa-pharmaceuticals-ads-ratio-change-1-ads-400-ordinary-shares-1-50-effective-october-26-2026-sec-filing-2610) — AInvest Wire, Oct 8, 2026
- [Biodexa Pharmaceuticals - files for resale of 2.56 mln ADSs by selling shareholders - SEC filing](https://www.ainvest.com/news/biodexa-pharmaceuticals-files-resale-2-56-mln-adss-selling-shareholders-sec-filing-2607) — AInvest Wire, Jul 15, 2026
  Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of 2,560,000 American Depositary Shares (ADSs) by selling shareholders, according to a recent SEC filing . The registration is part of the company’s ongoing efforts to…
- [Biodexa Pharmaceuticals - receives Health Canada approval to expand Phase 3 FAP trial into Canada](https://www.ainvest.com/news/biodexa-pharmaceuticals-receives-health-canada-approval-expand-phase-3-fap-trial-canada-2606) — AInvest Wire, Jun 29, 2026
  Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has announced that it has received regulatory approval from Health Canada to expand its Phase 3 Serenta clinical trial for eRapa into Canada. This development follows the successful activation of the first European site at the University of Bonn in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).